Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
18/06/2026 14:12
BRIEF-Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis June 18 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO SECURES FDA ORPHAN DRUG DESIGNATION FOR GRI-0621 (TAZAROTENE) IN IDIOPATHIC PULMONARY FIBROSIS
Source text: ID:nGNXmbsnr
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027